Aurinia Pharmaceuticals Inc (AUPH) exhibits 88.5% gross margins and 16.5% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 21.1x enterprise multiple and 4.8% implied options volatility.
Sustained 88.5% gross profitability converts into 37.1% operating margin and 16.5% ROIC, outpacing sector cost of capital.
ROIC: 16.5% // GM: 88.5%YoY revenue trajectory of +20.4% paired with 5.92% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +20.4% // FCF YLD: 5.92%Altman Z-Score of 8.33 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 8.33 // F-SCORE: 7/9Trading at 8.0x trailing P/E (6.7x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 8.0x // EV/EBITDA: 21.1xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $17.21 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 68.0% net margins.
NET MARGIN: 68.0% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for AUPH & activate live FRED threshold breach alerts.